BILLY MANUEL: Open Payments
NPI 1093293383 · SYRACUSE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,894 in 84 payments from 11 companies in 2025. Trend: 2023 $1,115 · 2024 $1,212 · 2025 $1,894
Food & beverage: $1,894
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $379 |
| Teva Pharmaceuticals USA, Inc. | 17 | $376 |
| ABBVIE INC. | 18 | $370 |
| Alkermes, Inc. | 14 | $202 |
| Axsome Therapeutics, Inc. | 7 | $128 |
| Neurocrine BioSciences, Inc. | 3 | $125 |
| Vanda Pharmaceuticals Inc. | 3 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Janssen Pharmaceuticals, Inc | 3 | $68 |
| Neos Therapeutics, LP | 1 | $20 |
Products named: CAPLYTA, VRAYLAR, UZEDY, ARISTADA, Auvelity, INGREZZA, AUSTEDO XR, FANAPT.
Industry payments across NY — which companies pay providers there.
